DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Accretion Nutraveda Ltd (ANL) share price today?

Accretion Nutraveda Ltd (ANL) is trading at ₹278 on the BSE, up 3.93% on the day. Source: DocStoX.

What is the PE ratio of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd has a price-to-earnings (PE) ratio of 5.2 in the Healthcare sector.

What is the market capitalisation of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd has a market capitalisation of approximately ₹201 crore.

Accretion Nutraveda Ltd

ANL·BSE·Healthcare

₹278.00▲ +10.50 (+3.93%)

Healthcare · Pharmaceuticals & Biotechnology

High-quality returns — 25% on equity

Day₹277.00

₹278.00

52W₹150

₹30085%

Open

₹277.00

High

₹278.00

Low

₹277.00

Prev Close

₹267.50

Volume

2.0K

VWAP

₹277.50

Snapshot

Key fundamentals

Market Cap

₹201 Cr

P/E Ratio

5.19Cheap

P/B Ratio

6.31

EPS

₹53.59

Book Value

₹42.41

ROE

24.80%Strong

ROCE

56.66%Efficient

Dividend Yield

0.00%

Debt / Equity

0.12Low

Face Value

₹10.00

52W High

₹300.00

52W Low

₹150.10

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹170

▼ 39.0%downside

Trading at ₹278 — 39% above our estimate

BearFair valueBull

₹82₹170₹195

/100

Business quality — High quality

Growth 50Profitability 89Efficiency 100Valuation 97

Plain English

Our view

High-quality returns — 25% on equity
Low debt relative to equity

Strengths

Low debt relative to equity
Strong returns on equity (25%)
Capital is working hard (ROCE 57%)
Reasonably priced at 5× earnings

How we got there

Fair value methods

Residual income

49% ROE fading to 12% over ~10 yrs, on ₹42 book

₹194

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹82

Analyst target

No analyst coverage

—

Blended fair value₹170

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (25%)
Capital is working hard (ROCE 57%)
Reasonably priced at 5× earnings
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

5.2Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

24.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

56.7%Efficient

Above 18% means capital is working hard

Debt/Eq

0.12Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹201 Cr

P/B

6.31

EPS

₹53.59

Div Yield

—

What changed

Recent changes

Domestic institutions-0.9% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 5.2×

Growth

Strong

+127% rev CAGR

Profitability

Excellent

24.8% ROE

Financial health

Rock solid

D/E 0.12

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹5.55L Cr

Trades2

VWAP₹277.50

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+126.5%

—

10Y

—

Profit

+162.6%

—

10Y

—

EPS

-3.5%

—

10Y

—

Profile

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Debtor days have increased from 60.3 to 88.1 days.
Working capital days have increased from 157 days to 352 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Domestic institutions reduced 0.89 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

73.5%0.00

Public

15.8%+1.58

FII / FPI

1.1%0.00

DII

6.1%-0.89

Others

3.6%

Total shareholders

396-31 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter73.48%

FII1.08%

DII6.11%

Public15.77%

Others3.56%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.[1]